

Helen L Reeves

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7352965/helen-l-reeves-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

4,958
citations

28
h-index

70
g-index

83
ext. papers

6,512
ext. citations

7.2
avg, IF

5.37
L-index

#	Paper	IF	Citations
64	Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. <i>Journal of Clinical Oncology</i> , 2015 , 33, 550-8	2.2	1097
63	From NASH to HCC: current concepts and future challenges. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 411-428	24.2	425
62	Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. <i>Journal of Hepatology</i> , 2014 , 60, 110-7	13.4	367
61	KLF6, a candidate tumor suppressor gene mutated in prostate cancer. <i>Science</i> , 2001 , 294, 2563-6	33.3	367
60	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014 , 5, 4309	17.4	362
59	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. <i>Cancer Research</i> , 2005 , 65, 1213-22	10.1	182
58	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 875-886.e6	6.9	141
57	Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. <i>Cancer Research</i> , 2004 , 64, 3885-91	10.1	137
56	Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. <i>Cancer Research</i> , 2005 , 65, 5761-8	10.1	133
55	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
54	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , 2004 , 40, 1047-52	11.2	130
53	The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 144-53	4	126
52	Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. <i>Journal of Hepatology</i> , 1996 , 25, 677-83	13.4	125
51	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016 , 114, 744-50	8.7	119
50	Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1234-45	4	88
49	Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. <i>Journal of Hepatology</i> , 2015 , 62, 1296-303	13.4	72
48	Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. <i>Journal of Hepatology</i> , 2000 , 32, 465-72	13.4	65

47	DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. <i>Clinical Cancer Research</i> , 2015 , 21, 925-33	12.9	63
46	Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2016 , 65, 305-13	13.4	63
45	In Vitro Cytotoxicity of 150 Chemicals to 3T3-L1 Cells, Assessed by the FRAME Kenacid Blue Method. <i>ATLA Alternatives To Laboratory Animals</i> , 1988 , 16, 84-95	2.1	59
44	Liquid biopsy for liver diseases. <i>Gut</i> , 2018 , 67, 2204-2212	19.2	57
43	Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012 , 55, 1083-93	11.2	50
42	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021 , 74, 775-782	13.4	50
41	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. <i>British Journal of Cancer</i> , 2018 , 118, 248-257	8.7	46
40	The CCR2 Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019 , 7, 371-390	7.9	42
39	Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. <i>Journal of Hepatology</i> , 2013 , 58, 1000-6	13.4	41
38	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. <i>International Journal of Cancer</i> , 2016 , 138, 206-16	7.5	33
37	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29
36	Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2018 , 73, 369-385	7.3	26
35	Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner. <i>EMBO Journal</i> , 2021 , 40, e106048	13	26
34	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021 , 75, 865-878	13.4	25
33	The role of phosphatidic acid in platelet-derived growth factor-induced proliferation of rat hepatic stellate cells. <i>Hepatology</i> , 2000 , 31, 95-100	11.2	24
32	Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. <i>Journal of Clinical Investigation</i> , 2020 , 130, 258-271	15.9	22
31	Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1078-1087	6.7	16
30	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020 , 9, 167-181	9.1	16

29	Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017 , 110, 73-81	2.7	15
28	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2016 , 48, 860-8	3.3	14
27	Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. <i>Journal of Hepatology</i> , 2015 , 62, 982-3	13.4	13
26	Assessment of the Hong Kong Liver Cancer Staging System in Europe. <i>Liver International</i> , 2016 , 36, 911-7.	7.9	12
25	NAFLD-Associated HCC: Progress and Opportunities. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 223-239	3.9	11
24	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021 , 3, 100260.	3	11
23	Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2016 , 115, 797-804	8.7	10
22	Reply:. <i>Hepatology</i> , 2005 , 41, 682-683	11.2	10
21	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. <i>Journal of Hepatocellular Carcinoma</i> , 2019 , 6, 23-30	5.3	9
20	Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases. <i>Organic and Biomolecular Chemistry</i> , 2015 , 13, 5279-84	3.9	9
19	Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. <i>Hepatobiliary Surgery and Nutrition</i> , 2021 , 10, 59-75	2.1	9
18	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. <i>Journal of Clinical and Experimental Hepatology</i> , 2016 , 6, 186-194	4.1	8
17	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.. <i>Nature Cancer</i> , 2022 , 3, 386-401	15.4	8
16	Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1563-1570	2.7	7
15	Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population. <i>Hepatic Medicine: Evidence and Research</i> , 2019 , 11, 47-67	3.4	6
14	Neutrophils as potential therapeutic targets in hepatocellular carcinoma.. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022 ,	24.2	5
13	A Role in the Genetic Predisposition to NAFLD-HCC?. <i>Cancers</i> , 2021 , 13,	6.6	5
12	Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort. <i>Journal of Clinical and Experimental Hepatology</i> , 2020 , 10, 17-29	4.1	5

11	Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases. <i>Chemical Science</i> , 2016 , 7, 2821-2826	9.4	4
10	High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2021 , 41, 828-836	7.9	4
9	Key features of the environment promoting liver cancer in the absence of cirrhosis. <i>Scientific Reports</i> , 2021 , 11, 16727	4.9	4
8	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. <i>Journal of Hepatology</i> , 2020 , 73, S13-S14	13.4	3
7	Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. <i>Hpb</i> , 2021 , 23, 495-505	3.8	3
6	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021 , 12, 555	9.8	2
5	Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area". <i>Journal of Hepatology</i> , 2014 , 60, 1330-1	13.4	1
4	Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy.. <i>Cell Death and Disease</i> , 2022 , 13, 143	9.8	1
3	Cell-free DNA TAPS provides multimodal information for early cancer detection. <i>Science Advances</i> , 2021 , 7, eabh0534	14.3	1
2	Mapping of population disparities in the cholangiocarcinoma urinary metabolome. <i>Scientific Reports</i> , 2021 , 11, 21286	4.9	0
1	Reply to Comment on "Circulating Neutrophils in patients with hepatocellular carcinoma". <i>British Journal of Cancer</i> , 2018 , 119, 781-782	8.7	